Table 2.

Associations with an empirical p-value < 0.05 between PRS for antidepressant response, psychiatric disorders, and symptom traits and placebo and vortioxetine response in the clinical test sample and the self-reported test sample.

PRS	Response measure	N	Best PT	N SNP	PRS R2	Full R2	Beta	SE	Emp. p
Clinical test sample—vortioxetine response
Clinically assessed response	HAM-A improvement	758	0.0001	87	0.012	0.122	0.82	0.28	0.026
Clinically assessed response	HAM-A PA improvement	758	0.0001	87	0.014	0.080	0.58	0.18	0.014
Clinical test sample—placebo response
MDD	HAM-A SA improvement	384	0.00005	730	0.022	0.056	0.54	0.19	0.011
Clinically assessed response	CPFQ & PDQ improvement	191	0.1	31466	0.053	0.088	4.82	1.54	0.004
Subjective well-being	MADRS improvement	441	0.001	834	0.019	0.043	−1.45	0.50	0.031
Subjective well-being	MADRS-6 improvement	441	0.001	834	0.019	0.042	−0.97	0.34	0.033
Subjective well-being	HAM-A SA improvement	384	0.005	2806	0.023	0.056	−0.57	0.20	0.028
Self-reported test sample—vortioxetine response
Schizophrenia	Self-reported response	742	0.0001	2325	0.036	0.048	−0.283	0.058	0.0001*

PRS polygenic risk score, MDD major depressive disorder, MADRS Montgomery-Åsberg Depression Rating Scale, MADRS-6 sub-scale of MADRS that focuses on the core symptoms of depression, HAM-A Hamilton Anxiety Rating Scale, HAM-A SA sub-scale of HAM-A that focuses on somatic anxiety, HAM-A PA sub-scale of HAM-A that focuses on psychic anxiety, PDQ Perceived deficits questionnaire, CPFQ Massachusetts General Hospital cognitive and physical functioning questionnaire, N no. of patients in association test, Best P_T Best P-value threshold as defined pr PRSice2, N SNP no. of SNPs for bets P_T, PRS R² variance explained by the PRS, Full R² variance explained by the full model (including covariates), Beta estimated coefficient, SE standard error, P P-value, Emp. p Empirical p-values.

*Significant following Bonferroni correction.